Kamaleshwaran Koramadai Karuppusamy, Mittal Bhagwant Rai, Harisankar Chidambaram Natrajan Balasubramanian, Bhattacharya Anish, Singh Shrawan Kumar, Mandal Arup K
Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Nucl Med. 2012 Apr;27(2):81-4. doi: 10.4103/0972-3919.110683.
Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients.
Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol.
BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the 153 positive cases, 108 (70%) had serum PSA > 100 ng/ml, 42 (28%) had PSA of 20-100 ng/ml and only 3 (2%) had PSA < 20 ng/ml. All the patients with PSA > 100 ng/ml had multiple skeletal metastasis. Of the 117 negative cases, 110 (94%) had a PSA < 20 ng/ml, 5 had between 20 and 100 ng/ml and only 2 (1.8%) had PSA > 100 ng/ml. Of the 113 patients with serum PSA < 20 ng/ml, 110 (97.4%) did not show any bony metastasis. 150/157 (95.5%) patients with PSA > 20 ng/ml had bone metastasis. Using this criterion, 110 (40.7%) scans would have been omitted.
Serum PSA < 20 ng/ml have high predictive value in ruling out skeletal metastasis. Our data are in corroboration with results from previous studies that BS should be performed only if PSA > 20 ng/ml. Using this cut-off, unnecessary investigation can be avoided. Avoiding BS in this group of patients would translate into a significant cost-saving and reduction in their psychological and physical burden.
放射性核素骨扫描(BS)曾经是检测前列腺癌骨转移的首选检查方法。如今,随着血清前列腺特异性抗原(PSA)检测的应用,临床医生确实有了一种及时且经济有效的方法来确定那些极不可能发生骨转移的患者。我们确定了PSA在预测前列腺癌患者骨扫描中骨骼转移情况的效用。
对过去3年中连续接受骨扫描的322例前列腺癌患者的病历进行回顾性分析。由于以下原因排除了52例:无法获得血清PSA、在血清PSA测量之前接受了激素或其他治疗以及/或者骨扫描,并且有骨转移症状。在其余270例病例中,评估了PSA值和骨扫描结果。按照标准方案用锝99m亚甲基二膦酸盐(MDP)进行骨扫描。
在270例患者中,骨扫描结果显示153例(56%)为阳性,117例(46%)为阴性。在153例阳性病例中,108例(70%)血清PSA>100 ng/ml,42例(28%)PSA为20 - 100 ng/ml,只有3例(2%)PSA<20 ng/ml。所有PSA>100 ng/ml的患者都有多处骨骼转移。在117例阴性病例中,110例(94%)PSA<20 ng/ml,5例PSA在20至100 ng/ml之间,只有2例(1.8%)PSA>100 ng/ml。在113例血清PSA<20 ng/ml的患者中,110例(97.4%)未显示任何骨转移。PSA>20 ng/ml的患者中有150/157例(95.5%)发生了骨转移。采用这一标准,110次(40.7%)扫描本可省略。
血清PSA<20 ng/ml在排除骨骼转移方面具有很高的预测价值。我们的数据与先前研究结果一致,即只有当PSA>20 ng/ml时才应进行骨扫描。采用这一切点,可以避免不必要的检查。在这组患者中避免进行骨扫描将显著节省费用,并减轻他们的心理和身体负担。